PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00243503
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1083
- Registration Number
- NCT00242710
- Locations
- 🇺🇸
Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00240747
- Locations
- 🇺🇸
Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00239928
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00232154
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
- Conditions
- Interventions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 408
- Registration Number
- NCT00227188
- Locations
- 🇪🇸
Pfizer Investigational Site, Bilbao, Spain
Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
- Conditions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 753
- Registration Number
- NCT00227240
- Locations
- 🇩🇪
Pfizer Investigational Site, Munich, Germany
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00226811
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT00225121
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00219622
- Locations
- 🇲🇽
Pfizer Investigational Site, Monterrey, Nuevo León, Mexico